On Tuesday, Shares of salesforce.com, inc. (NYSE:CRM), gained 1.29% to $77.24.
Salesforce, declared the kick off of the all-new Sales force World Tour in New York City on Nov. 18, 2015 at the Jacob K. Javits Convention Center. Sales force President and Vice Chairman Keith Block will deliver a keynote outlining how businesses can accelerate their digital transformations and become customer companies.
The Sales force World Tour
Over the last 16 years, Sales force has expanded and redefined CRM, bringing social, mobile, data science and IoT technologies to its trusted cloud platform. The Sales force Customer Success Platform enables companies to connect with customers in new ways, run their business from their phone, create 1-to-1 customer journeys and make smarter, more predictive decisions from anywhere in real time.
The Sales force World Tour is a global road show where businesses can learn how the Salesforce Customer Success Platform empowers them to accelerate their digital transformations and become customer companies. Events feature keynotes from Salesforce executives and other influencers, specialized breakout sessions for every role and industry, live demos of cutting-edge technologies and showcase how customers are using Salesforce to grow their business. Future Salesforce World Tour destinations comprise: Los Angeles, Minneapolis, Tokyo, Atlanta, Houston, Dallas, Seattle, Hannover, Chicago, Boston, Melbourne, Amsterdam, Washington D.C., London and Paris.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship administration to various businesses and industries worldwide. The company offers enterprise cloud computing apps and platform services, counting Sales Cloud for sales force automation, which enables companies to store data, access accurate customer and prospect information, track leads and progress, forecast opportunities, and collaborate around any sale on desktop and mobile devices; Service Cloud that enables companies to connect address customers service and support needs; and Marketing Cloud, which enables companies to map customer journeys to digital marketing interactions through email, mobile, social, Web, and connected products.
Shares of 2U Inc (NASDAQ:TWOU), declined -1.53% to $21.23, during its last trading session.
2U Inc. declared that CEO and co-founder Chip Paucek will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference on November 19, 2015. 2U is a leading provider of cloud-based software-as-a-service technology fused with technology-enabled services that enables leading nonprofit colleges and universities to deliver their high-quality degree programs online.
2U, Inc. provides cloud-based software-as-a-service (SaaS) solutions for nonprofit colleges and universities to deliver education to qualified students. Its cloud-based SaaS platform solutions comprise online campus, an online learning platform that enables its clients to offer educational content together with instructor-led classes in a live, intimate, and engaging setting through proprietary Web-based and mobile applications; and content administration system, which enables its clients to author, review, and deploy asynchronous content into their online programs.
Finally, Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), ended its last trade with 5.24% gain, and closed at $27.30.
Sarepta Therapeutics, declared that the Annals of Neurology published online [link to final article] positive efficacy and safety results from a Phase IIb long-term open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The study found that at three years of treatment, patients practiced a slower rate of disease progression when contrast to untreated matched historical controls and the investigational drug continued to be well-tolerated.
This analysis used historical data from the Italian Telethon Network and the Leuven Neuromuscular Reference Group for comparative analysis of 6MWT performance at baseline and Months 12, 24, and 36. Patients were matched to the eteplirsen group based on age, corticosteroid use and genotype.
At 36 months, eteplirsen-treated patients demonstrated a statistically noteworthy difference of 151 meters in six minute walk test (6MWT), contrast to the external cohort. The eteplirsen-treated patients practiced a lower incidence of loss of ambulation (16.7%) contrast to natural history control patients (46.2%).
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.